title: [Flavonoids of puerarin versus tanshinone II A for ischemic stroke: a randomized controlled trial].
abstract: BACKGROUND
  Flavonoids are widely used today in the treatment of ischemic stroke. The therapeutic effects and functions of flavonoids are, therefore, generating more and more interest.
  
  
  OBJECTIVE
  To investigate the therapeutic effects and functions of flavonoids of puerarin in treating patients with ischemic stroke.
  
  
  METHODS
  A total of 67 inpatients suffering from ischemic stroke from the Department of Neurology, Changhai Hospital in China were divided into two groups randomly, the treatment group, which was treated with flavonoids of puerarin, and the control group, administered with tanshinone II A sulfate instead.
  
  
  METHODS
  Defects in neurological function were evaluated according to the National Institutes of Health Stroke Scale (NIHSS) on the first day of onset. Lactate dehydrogenase (LDH), serum interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) levels were determined by radioimmunoassay on the second trial day. After a 14-day treatment, LDH, serum IL-6 and BDNF levels and NIHSS score were also detected, and CT perfusion imaging was used to measure and analyze the regional cerebral blood flow (rCBF), regional cerebral blood volume (rCBV) and mean transit time (MTT).
  
  
  RESULTS
  On the first day, NIHSS scores of the two groups were similar. On the second day there was no significant difference in LDH and IL-6 levels between the treatment group and the control group. After a 14-day treatment, LDH and IL-6 levels and the NIHSS score in the treatment group were lower than those in the control group (P<0.05). There was no significant difference in BDNF levels in the two groups. After 14 d, the CT perfusion imaging demonstrated that the treatment group showed more effective blood perfusion than the control group.
  
  
  CONCLUSIONS
  Flavonoids of puerarin can restrain the increase of IL-6 after acute ischemic stroke, and depress the LDH raised by reperfusion after cerebral ischemia. It can also enhance blood perfusion of the ischemic region.
authors.affiliation: Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
authors.forename: Xiao-ying
authors.initials: XY
authors.lastname: Bi
authors.forename: Li-xun
authors.initials: LX
authors.lastname: Zhu
authors.forename: Yi-qing
authors.initials: YQ
authors.lastname: Qiu
authors.forename: Su-ju
authors.initials: SJ
authors.lastname: Ding
authors.forename: Ben-qiang
authors.initials: BQ
authors.lastname: Deng
mesh_terms: D045784:Abietanes / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy*; D019208:Brain-Derived Neurotrophic Factor / Q000032:analysis; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007529:Isoflavones / Q000627:therapeutic use*; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D020521:Stroke / Q000188:drug therapy*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D045784:Abietanes; D019208:Brain-Derived Neurotrophic Factor; D015850:Interleukin-6; D007529:Isoflavones; D014665:Vasodilator Agents; C021751:tanshinone; D007770:L-Lactate Dehydrogenase; C033607:puerarin